Haematology Peter MacCallum CC & Royal Melbourne

This is the account of Clinical Haematology at Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Australia. NEWS only; not referrals.

[Michael Dickinson @mike_dickinson1]

#Glofitamab is very active in #mantle cell #lymphoma: Very pleased to show it in this data now available @JCO_ASCO https://t.co/Cc2o9iH7aG big thanks to co-investigators @lymphclinician et al, and to my team @haem_pmcc_rmh #lymsm @PeterMacCC

[Haematology Peter MacCallum CC & Royal Melbourne @Haem_pmcc_rmh]

Congratulations to the big team that made this IIT happen!

[Eddie Cliff @Eddie_Cliff]

Just out in @JCO_ASCO the VALDAC study of LDAC+Ven for MRD relapse or oligoblastic relapse in AML

MRD group: 46% MRD negativity
oligoblastic group: 73% CR/CRh/CRi

2 year OS 67% in MRD group, 53% in oligoblastic group

https://t.co/PIy2avK0f7 @Haem_pmcc_rmh @PeterMacRes #leusm

[Michael Dickinson @mike_dickinson1]

So pleased to work with @JenCrombieMD @falchi_Lorenzo and a great team of authors from around the world and from a variety of treatment settings on these recommendations for #bispecifics. Now available @bloodjournal #lymsm @lymphoma @lymphomaoz https://t.co/JLzn6XlTEN

[Mark Dawson @MAF_Dawson]

👇🏾This guy is a superstar 🤩

[Andrew M. Evens, DO, MBA, MSc @DrAEvens]

CAR T-cells and Time-Limited Ibrutinib as Treatment for Relapsed/Refractory Mantle Cell Lymphoma: Phase II TARMAC Study https://t.co/v0JvGYOG4E

👉A really smart study w/ time-limit BTK in a difficult to treat #lymphoma, esp p53 mutated. @BloodJournal | @ASH_hematology @michaeldi

[Steve Lane @StevenLane_QIMR]

Amazing science and clinical advances from the #blood2023 Presidential Symposium - an honour to co-chair this session
@hsanz_org_au @THANZBlood

[Michael Dickinson @mike_dickinson1]

#CART and fixed #ibrutinib for #Mantle cell #lymphoma in @bloodjournal. More evidence that immunotherapy may help with high-risk molecular subtypes. Congrats to @adrianminson for driving this lightning-fast @petermacres IIT as part of his PHD! #lymsm https://t.co/nLFWCZxuzE

[Eddie Cliff @Eddie_Cliff]

Venetoclax: a fantastic @WEHI_research @TheRMH @Haem_pmcc_rmh Melbourne success story (with collab @DanaFarber) - great to see the fab Mary Ann presenting it #EHA2023

#VitaminV

@thomaseliotlew @victorshiyulin @DrMDavids @MAF_Dawson @mike_dickinson1

[Michael Dickinson @mike_dickinson1]

@AdrianMinson presented the preliminary results from our Aussie IIT of #glofitamab in combination with RCHP-Pola or RCHOP as first treatment in high risk younger patients with #DLBCL @EHA_Hematology #EHA2023 #lymsm Thanks to our sites and @PeterMacCC @Haem_pmcc_rmh @PeterMacRes

[Michael Dickinson @mike_dickinson1]

#pembrolizumab is deliverable and effective as a monotherapy first treatment of #hodgkin #lymphoma in very frail patients. Pleased to present #EHA2023 @EHA_Hematology and more detail to follow @icmlugano Thanks to sites for years of effort! @JudithTrotman1 #lymsm @PeterMacCC

[Michael Dickinson @mike_dickinson1]

Faster stronger fitter! #Rapcabtagene autoleucel #YTB323 RAPID autologous #CART for #DLBCL #lymphoma: The preclinical and early clinical paper now @CD_AACR online https://t.co/MnglCARSbY So proud of this -and thanks to @PeterMacCC @Haem_pmcc_rmh #lymsm

[ASIDANZ @ASIDANZ]

This is everything. @monicaslavin @TheAdelaideOval #asid23

[Haematology Peter MacCallum CC & Royal Melbourne @Haem_pmcc_rmh]

Well deserved kudos for our colleague who is not only productive researcher and clinician, but also a great mentor to others.

[Peter Mac Research @PeterMacRes]

Congratulations to Mary Ann Anderson, world leader in #CLL treatment, on her promotion to Honorary Clinical Associate Professor in the Sir Peter MacCallum Department of Oncology at the University of Melbourne. @UniMelbMDHS @PeterMacCC @WEHI_research. A very well deserved promo.👏

[Haematology Peter MacCallum CC & Royal Melbourne @Haem_pmcc_rmh]

We are looking for a clinical data manager to join our team and contribute to research and quality projects in haematology. https://t.co/zSym5jNjup

[Michael Dickinson @mike_dickinson1]

Results of a multi-centre @PeterMacCC trial of #CART + #ibrutinib in #mantle cell #lymphoma were presented at #ASH22 by @AdrianMinson Durable responses even in high-risk subtypes. Thx to @chanyooncheah @nadahamad for contributing #lymsm https://t.co/vnrwvFjp1i

[Jeff Szer @marrow]

@Haem_pmcc_rmh

[Michael Dickinson @mike_dickinson1]

Delighted that #glofitamab pivotal data for DLBCL is now online @NEJM. 39.4% CR in patients with the most common aggressive #lymphoma, Fixed course, durable remissions, good safety profile, I hope this data changes practice for patients with R/R #DLBCL #ASH22 #lymsm @DocHutchings

[VJHemOnc @VJHemOnc]

We had a lovely interview here at #ASH22 with @AdrianMinson of @Haem_pmcc_rmh on the Tarmac study, novel combinations in NHL, PET-adapted therapy in DLBCL & more!

@ASH_hematology #LymSM #ImmunoOnc #CARTcell #HemOnc #DLBCL

[Eddie Cliff @Eddie_Cliff]

Congrats to Prof @srpasricha on the @AAHMS_health Jian Zhou Medal - Santa is a true guru of iron and does awesome research in iron, anaemia, and global health. Very well-deserved! @Haem_pmcc_rmh @marrow @thomaseliotlew

[Lymphoma Hub @lymphomahub]

CONGRESS #EHA2022 | @mike_dickinson1 presents the latest data of glofitamab, CD20xCD3 bispecific, in patients with r/r DLBCL and a median of 3 PL, including #CARTcell. The primary endpoint was met: fixed-duration treatment led to a 39.4% CR rate #lymphoma #lymsm